XML 33 R17.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other Operating Expenses | 12 Months Ended
--- | ---
Dec. 28, 2018
Other Income and Expenses [Abstract] |
OTHER OPERATING EXPENSES | 11.) OTHER OPERATING EXPENSES OOE for fiscal years 2018, 2017 and 2016 is comprised of the following (in thousands):
| 2018 |  | 2017 |  | 2016
Strategic reorganization and alignment | $ | 10,624 |  |  | $ | 5,891 |  |  | $ | — |
Manufacturing alignment to support growth | 3,089 |  |  | — |  |  | — |
Consolidation and optimization initiatives | 844 |  |  | 12,803 |  |  | 25,510 |
Acquisition and integration costs | — |  |  | 10,870 |  |  | 28,112 |
Asset dispositions, severance and other | 1,508 |  |  | 6,874 |  |  | 6,791 |
Other operating expenses | $ | 16,065 |  |  | $ | 36,438 |  |  | $ | 60,413 |
Strategic reorganization and alignment During the fourth quarter of 2017, the Company began to take steps to better align its resources in order to enhance the profitability of its portfolio of products. This includes improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan of between approximately $28 million to $30 million, of which an estimated $16 million to $20 million are expected to result in cash outlays. During 2018, the Company incurred charges relating to this initiative which primarily included severance and personnel related costs for terminated employees and fees for professional services. These expenses were primarily recorded within the Medical segment. As of December 28, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $16.5 million. These actions are expected to be substantially completed by the end of 2019. Manufacturing alignment to support growth In 2017, the Company initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $9 million to $11 million, the majority of which are expected to be cash expenditures, and capital expenditures of between approximately $4 million to $6 million. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 28, 2018, total expense incurred for this initiative since inception was $3.4 million. These actions are expected to be substantially completed by the end of 2019. Consolidation and optimization initiatives In 2014, the Company initiated plans to transfer certain manufacturing functions performed at its facility in Beaverton, OR to a new facility in Tijuana, Mexico. Additionally, during 2016, the Company announced it would be closing its facility in Clarence, NY after transferring the machined component product lines manufactured in that facility to other Integer locations in the U.S. Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical segment. The Company does not expect to incur any additional material costs associated with these activities as these activities are substantially complete. The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):
| Severance and Retention |  | Accelerated Depreciation/ Asset Write-offs |  | Other |  | Total
December 29, 2017 | $ | 1,308 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,308 |
Restructuring charges | 3,812 |  |  | 514 |  |  | 10,231 |  |  | 14,557 |
Write-offs | — |  |  | (514 | ) |  | — |  |  | (514 | )
Cash payments | (3,452 | ) |  | — |  |  | (10,029 | ) |  | (13,481 | )
December 28, 2018 | $ | 1,668 |  |  | $ | — |  |  | $ | 202 |  |  | $ | 1,870 |
(11.) OTHER OPERATING EXPENSES (Continued) Acquisition and Integration Expenses The Company did not incur any additional costs associated with these activities during the year ended December 28, 2018. Acquisition and integration costs are predominantly related to the acquisition of LRM and primarily include professional, consulting, severance, retention, relocation, and travel costs. Integration costs primarily include professional, consulting, severance, retention, relocation, and travel costs. The $0.4 million of acquisition and integration costs accrued as of December 29, 2017 were paid during the first quarter of 2018. These projects were completed as of December 29, 2017. Asset Dispositions, Severance and Other During 2018, 2017 and 2016, the Company recorded losses in connection with various asset disposals and/or write-downs. The 2017 amount also includes approximately $5.3 million in expense related to the Company’s leadership transitions, which were recorded within the corporate unallocated segment. In addition, the 2016 amount includes the legal and professional costs incurred in connection with the Spin-off of $4.4 million. Expenses related to the Spin-off were primarily recorded within the corporate unallocated and the Medical segment.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration